These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8664132)

  • 41. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O; Hubert A; Gabizon AA
    Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells.
    Tacka KA; Szalda D; Souid AK; Goodisman J; Dabrowiak JC
    Chem Res Toxicol; 2004 Nov; 17(11):1434-44. PubMed ID: 15540941
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
    Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
    Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
    Jarvis IW; Meczes EL; Thomas HD; Edmondson RJ; Veal GJ; Boddy AV; Ottley CJ; Pearson DG; Tilby MJ
    Biochem Pharmacol; 2012 Jan; 83(1):69-77. PubMed ID: 22015635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
    Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
    Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer.
    Tegeder I; Bräutigam L; Seegel M; Al-Dam A; Turowski B; Geisslinger G; Kovács AF
    Clin Pharmacol Ther; 2003 May; 73(5):417-26. PubMed ID: 12732842
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
    Evans DL; Tilby M; Dive C
    Cancer Res; 1994 Mar; 54(6):1596-603. PubMed ID: 8137265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.
    Espina M; Corte-Rodríguez M; Aguado L; Montes-Bayón M; Sierra MI; Martínez-Camblor P; Blanco-González E; Sierra LM
    Metallomics; 2017 May; 9(5):564-574. PubMed ID: 28425536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
    Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
    J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aromatic DNA adducts in larynx biopsies and leukocytes.
    Szyfter K; Hemminki K; Szyfter W; Szmeja Z; Banaszewski J; Yang K
    Carcinogenesis; 1994 Oct; 15(10):2195-9. PubMed ID: 7955053
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Constancy in integrated cisplatin plasma concentrations among pediatric patients.
    Goodisman J; Souid AK
    J Clin Pharmacol; 2006 Apr; 46(4):443-8. PubMed ID: 16554452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumour resistance to cisplatin: a modelling approach.
    Marcu L; Bezak E; Olver I; van Doorn T
    Phys Med Biol; 2005 Jan; 50(1):93-102. PubMed ID: 15715425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
    Nannan Panday VR; de Wit R; Schornagel JH; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 1999; 44(4):349-53. PubMed ID: 10447584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
    Blommaert FA; Michael C; Terheggen PM; Muggia FM; Kortes V; Schornagel JH; Hart AA; den Engelse L
    Cancer Res; 1993 Dec; 53(23):5669-75. PubMed ID: 8242622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
    J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
    Tonda ME; Murry DJ; Rodman JH
    Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro antitumor activity, intracellular accumulation, and DNA adduct formation of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)] platinum (II) suspended in lipiodol.
    Kishimoto S; Miyazawa K; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Jan; 91(1):99-104. PubMed ID: 10744050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.